Development of cancer chemopreventive agents: oltipraz as a paradigm.
about
Case-control study of an acute aflatoxicosis outbreak, Kenya, 20041,2-dithiole-3-ones as potent inhibitors of the bacterial 3-ketoacyl acyl carrier protein synthase III (FabH)Aflatoxin: a 50-year odyssey of mechanistic and translational toxicologyChemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiinsAntioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase. A new role for leukotriene B4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductaseSmall molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agentsThe complexity of the Nrf2 pathway: beyond the antioxidant responseSensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice1,2-dithiole-3-thione and its structural analogue oltipraz are potent inhibitors of dibenz.Summary of information on human CYP enzymes: human P450 metabolism data.Analyzing microarray data with transitive directed acyclic graphsMechanisms and functions of Nrf2 signaling in Drosophila.Interactions of the major metabolite of the cancer chemopreventive drug oltipraz with cytochrome c: a novel pathway for cancer chemopreventionComplete protection against aflatoxin B(1)-induced liver cancer with a triterpenoid: DNA adduct dosimetry, molecular signature, and genotoxicity threshold.Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer.A versatile ΦC31 based reporter system for measuring AP-1 and Nrf2 signaling in Drosophila and in tissue culture.Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter.Chemoprotective potential of phase 2 enzyme inducers.Targeting NRF2 signaling for cancer chemoprevention.The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa.An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride.Inactivation of protein tyrosine phosphatases by oltipraz and other cancer chemopreventive 1,2-dithiole-3-thiones.7-Ethynylcoumarins: selective inhibitors of human cytochrome P450s 1A1 and 1A2.Bakuchiol Is a Phenolic Isoprenoid with Novel Enantiomer-selective Anti-influenza A Virus Activity Involving Nrf2 Activation.Chemopreventive effect of oltipraz on AFB(1)-induced hepatocarcinogenesis in tree shrew model.Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in DrosophilaPharmacological induction of ferritin prevents osteoblastic transformation of smooth muscle cells.Dithiolethiones for cancer chemoprevention: where do we stand?Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway.Reducing human exposure to aflatoxin through the use of clay: a review.A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by aflatoxinTransgenic expression of aflatoxin aldehyde reductase (AKR7A1) modulates aflatoxin B1 metabolism but not hepatic carcinogenesis in the rat.5,6-Dihydrocyclopenta[c][1,2]-dithiole-3(4H)-thione is a promising cancer chemopreventive agent in the urinary bladder.Hydrogen peroxide is a second messenger in phase 2 enzyme induction by cancer chemopreventive dithiolethiones.Preparation of Disubstituted Phenyl Propargyl Alcohols, their Use in Oxathiolene Oxide Synthesis, and Evaluation of the Oxathiolene Oxide Products as Anticarcinogenic Enzyme Inducers.Targeting the Nrf2 pathway against cardiovascular disease.Identification of the interactive interface and phylogenic conservation of the Nrf2-Keap1 system.The Effects of Oltipraz on Tissue Regeneration in the Process of Wound Healing: A Stereological Study.Covalent inhibition of protein tyrosine phosphatases.Protection against aflatoxin B1-induced cytotoxicity by expression of the cloned aflatoxin B1-aldehyde reductases rat AKR7A1 and human AKR7A3
P2860
Q24534464-FF2E4BDD-5A41-41E0-BD27-FA63FEB282F6Q24564306-01EBF5DF-EEE3-4BD4-BEBF-C3683D2B17F3Q24617120-C5EFAD4F-F0C9-40DD-ABC9-07566710CD3AQ28201073-CA989647-3049-42FC-A9A1-EC0825DAC5B3Q28214506-23D1DE00-4711-4309-8EFA-AF6120F5B2DDQ28386244-8A9CBE50-5837-4DAE-8C05-FD5B3C0AED3BQ28389296-E7A8B3E7-BEE5-4FE1-BE56-12265EBED6B8Q29615438-56725CCB-B6DB-437D-8E4F-67016F7CE343Q31811667-51FD02B4-BE80-4E5D-BD3B-A8EA380D8E30Q32103802-E1B180CF-2399-4396-8F93-CF9C12E8B978Q33410446-F5B0C13A-941B-4F16-8781-D771710EE8FDQ33763536-DC841D22-7E41-49C5-AEED-DD5ED92080E5Q33815474-61C837BB-6AB4-44F2-BFC1-E156599647D7Q33848142-4184A1BB-AB29-438F-8D4A-1380EC4C437DQ33952070-0B2AA8FA-73A1-43BC-9BF5-9C508E51FD73Q34235097-F3AD0B4A-E8BB-470F-A3A1-3750ADFFA4D7Q34278223-4C41CA70-A1C3-4DBE-828D-57612F2E533BQ34969274-8F4E91E4-6378-494A-BD5B-A8319E20D4DBQ35001318-5398CA03-FBB8-4D47-8458-DC1BC70AAEBEQ35048243-67C34B28-C34D-4434-8D89-73568213D8D1Q35086803-907F4333-7CC5-4015-AD3F-A3A86FDF9901Q35661008-4CAE15DC-2AB5-46E4-8289-1397EA3E46D1Q35981085-C05789FC-6BBF-425D-85B7-CE6BC4831B89Q36282965-47754147-81AF-4F74-AD09-2C9FA60AA210Q36397692-1CAB3516-086A-4177-8CB7-C3AD75253E15Q36481370-D735B08A-4E70-4590-8F73-8C8FDE27EA10Q36504284-08BAF270-1FA9-46E5-B0E2-EF42D3BBD3CEQ37002516-651EDC81-D8DC-401C-9D08-1AC7CCE8EEFFQ37062266-0F7DFA6C-6BCD-46E1-BD5D-D2FA20DA6E96Q37089066-2B7F9506-726D-46A2-BC08-58BB69030C00Q37156426-C6330D2B-4184-4727-98CE-85877A3BE349Q37175443-F710BA6B-D70E-40A7-9F9D-84BF02C5A8CFQ37196960-363868F6-981D-4174-94AC-86948BB6BB76Q37371494-622A2C8F-D60E-4CD9-8986-9601153AEB88Q37401129-F944898B-1A8A-4CAA-9E1A-CE22321BDA89Q37521075-C60319B2-F58F-41EF-895C-E5AAC924C7DFQ38363758-73C961EE-4C23-44A1-8F52-E5836779D251Q38679798-624A5E0A-AFA1-49E3-81CE-43877E21D7DCQ39324501-11E1538F-A07E-4FEC-9567-FC1A4958E880Q39991413-D2C66EFE-CC74-4274-825E-FA2A95ECE704
P2860
Development of cancer chemopreventive agents: oltipraz as a paradigm.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@ast
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@en
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@nl
type
label
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@ast
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@en
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@nl
prefLabel
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@ast
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@en
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@nl
P2093
P356
P1476
Development of cancer chemopreventive agents: oltipraz as a paradigm.
@en
P2093
Curphey TJ
Groopman JD
Kensler TW
Roebuck BD
P304
P356
10.1021/TX980185B
P577
1999-02-01T00:00:00Z